Zou Bin

Company: Axcynsis Therapeutics

Job title: Founder & Chief Executive Officer

Seminars:

12:30pm Discovery of AT03-65, a Highly Selective Anti-CLDN6 ADC With a Proprietary Payload 12:30 pm

Overview of current and next generation of ADCs Discovery of AT03-65, a novel payload ADC using AxcynDOTTM technology Preclinical journey of AT03-65 and progression into the clinicRead more

day: Day Two Discovery Track

12:00pm Panel Discussion: What is the Next Frontier Within ADC Payloads? 12:00 pm

What are the emerging trends in ADC payloads in APAC, the US and Europe? Exploring the most novel MOAs that are entering preclinical development and the value proposition of each compared to tubulin inhibitors and DNA damaging agents Considering the difference in physicochemical properties and PK profiles of next generation versus traditional ADC payloadsRead more

day: Day Two Discovery Track